
Opinion|Videos|April 18, 2025
Treatment Escalation and De-escalation Strategies in Pediatric AD: Positioning Ruxolitinib Cream in Clinical Decision-Making
Author(s)James Song, MD, FAAD
James Song, MD, FAAD, discusses how clinicians should evaluate treatment response based on objective measures including BSA involvement, EASI scores, and pruritus ratings when determining whether to escalate from topical ruxolitinib to systemic therapy or de-escalate to maintenance treatment in pediatric atopic dermatitis patients.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- How do you determine when to escalate or de-escalate treatment in pediatric AD, and where might ruxolitinib cream fit in that decision-making process?
Advertisement
Related to this article

A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.

SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.

Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.

No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.

Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
4
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
5







